Structure Therapeutics (NASDAQ:GPCR) Trading Up 5.8% - Time to Buy?

Key Points

• Structure Therapeutics' stock rose 5.8% to $19.61, despite a significant drop in trading volume compared to its average session.
• Analysts generally maintain a "Buy" rating on the stock, with a consensus price target of $75.71, indicating potential for significant upside.
• The company reported a quarterly loss of ($0.36) EPS, missing estimates, while institutional investors own over 91% of the stock.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report)'s stock price traded up 5.8% on Friday . The company traded as high as $19.66 and last traded at $19.61. 150,029 shares were traded during trading, a decline of 83% from the average session volume of 872,485 shares. The stock had previously closed at $18.53.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Cantor Fitzgerald reiterated an "overweight" rating and set a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, June 23rd. JMP Securities decreased their price target on shares of Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating for the company in a research note on Thursday, August 7th. HC Wainwright decreased their price target on shares of Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. Citigroup assumed coverage on shares of Structure Therapeutics in a research note on Friday, May 2nd. They set a "buy" rating and a $60.00 price target for the company. Finally, Guggenheim decreased their price target on shares of Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating for the company in a research note on Thursday, August 7th. Eight analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Structure Therapeutics presently has an average rating of "Buy" and a consensus target price of $75.71.

Structure Therapeutics Trading Down 0.7%

The company's 50 day moving average price is $19.42 and its 200 day moving average price is $21.31. The company has a market cap of $1.08 billion, a price-to-earnings ratio of -17.80 and a beta of -1.89.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08). Sell-side analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current year.

Hedge Funds Weigh In On Structure Therapeutics

A number of large investors have recently made changes to their positions in the stock. State of Wyoming purchased a new position in shares of Structure Therapeutics in the 2nd quarter valued at about $28,000. MASO CAPITAL PARTNERS Ltd purchased a new position in shares of Structure Therapeutics in the 2nd quarter valued at about $270,000. Headlands Technologies LLC increased its holdings in shares of Structure Therapeutics by 555.5% in the 2nd quarter. Headlands Technologies LLC now owns 22,338 shares of the company's stock valued at $463,000 after purchasing an additional 18,930 shares in the last quarter. Engineers Gate Manager LP purchased a new position in shares of Structure Therapeutics in the 2nd quarter valued at about $329,000. Finally, BNP Paribas Financial Markets increased its holdings in shares of Structure Therapeutics by 1,357.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 65,836 shares of the company's stock valued at $1,365,000 after purchasing an additional 61,318 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.